Wilson's disease (WD) is an autosomal recessive disorder of hepatic copper transport caused by mutations in the ATP7B gene (chromosome 13q14.3). The ATP7B protein is a P-type ATPase with two critical functions in hepatocytes:
Two consequences of ATP7B loss
- Failure to incorporate copper into ceruloplasmin — ceruloplasmin is secreted as an apoprotein (apoceruloplasmin) without copper, leading to low serum ceruloplasmin levels
- Failure to excrete copper into bile — copper cannot be eliminated via the primary excretory route, causing progressive hepatic accumulation and subsequent organ spillover
The result is copper accumulation that begins in the liver and, once hepatic storage capacity is exceeded, overflows into the brain, kidneys, cornea, and red blood cells. WD affects approximately 1 in 30,000 individuals worldwide; the carrier frequency is approximately 1 in 90.
ATP7B's two failures: low serum ceruloplasmin (left) and hepatic copper accumulation with tissue spillover (main path)
Quick recall
1/3
Why is total serum copper LOW in WD despite copper overload?
Tap to reveal →
WD is a disease of young people — typically presenting between ages 5–35 years, though cases have been reported up to age 40–50 (AASLD 2008, PMID 18506894; EASL 2012, PMID 22340672). Presentations are heterogeneous and may overlap across organ systems. Click each card to expand the clinical details.
Hepatic
Liver Involvement
Click to expand
Neuropsychiatric
Brain and Behavior
Click to expand
Ophthalmologic + Other
Eyes and Systemic
Click to expand
WD-ALF Clue Set
Young patient + ALF + Coombs-negative hemolytic anemia + low ALP + low ceruloplasmin = WD until proven otherwise. This constellation should trigger immediate evaluation and urgent liver transplant listing — WD-ALF is almost uniformly fatal without transplantation.Copper studies in WD require careful interpretation. The relationship between ceruloplasmin and total serum copper is counterintuitive and is a common source of error.
Counterintuitive copper test interpretation
In WD, total serum copper is often LOW — because ~90% of serum copper is ceruloplasmin-bound. When ceruloplasmin is depleted by ATP7B loss, total copper falls with it. The diagnostically relevant fraction is free (non-ceruloplasmin-bound) copper, which is elevated in WD (>25 µg/dL). Free copper = total serum copper − (ceruloplasmin × 3).| Test | Finding in WD | Pitfall |
|---|---|---|
| Serum ceruloplasmin | <20 mg/dL (normal 20–35 mg/dL) | Also low in protein malnutrition, protein-losing enteropathy, and severe liver disease of any cause; may be falsely normal in acute inflammation or pregnancy (ceruloplasmin is an acute-phase reactant) |
| Total serum copper | Often LOW — because ~90% of serum copper is ceruloplasmin-bound; low ceruloplasmin = low total copper | Counterintuitive: a copper overload disease can present with low total serum copper — this is because the carrier protein (ceruloplasmin) is depleted |
| Free (non-ceruloplasmin-bound) copper | Elevated >25 µg/dL; calculated: total serum copper − (ceruloplasmin × 3) | Most diagnostically relevant copper fraction; not directly measured — calculated from total copper and ceruloplasmin |
| 24-hour urine copper | >100 µg/day in symptomatic patients (diagnostic threshold); >40 µg/day in asymptomatic at-risk relatives (concerning) | Incomplete collection is common; always verify with urine creatinine to confirm adequacy |
| Serum ALT/AST | Elevated; may be disproportionately LOW in fulminant WD due to hepatocyte depletion | In fulminant WD-ALF, ALT can be paradoxically low despite massive hepatic necrosis — reflects loss of hepatocytes rather than intact hepatocyte injury |
| Coombs-negative hemolytic anemia | Direct antiglobulin test (DAT) negative; copper-mediated erythrocyte membrane damage causing intravascular hemolysis | Key diagnostic clue in WD-ALF; must distinguish from autoimmune hemolytic anemia (which is DAT-positive) |
| Alkaline phosphatase (ALP) | Often LOW or paradoxically normal in WD-ALF | In ALF from other causes (acetaminophen, ischemic hepatitis, viral), ALP is elevated or normal — a low ALP in the setting of ALF is a specific clue pointing toward WD |
Quick recall
1/3
Counterintuitive pearl: Which serum copper test is LOW in Wilson's disease?
Tap to reveal →
The Leipzig score is the standard validated diagnostic algorithm for Wilson's disease, incorporating clinical, biochemical, histologic, and genetic features into a single composite score. It is the recommended approach when the diagnosis is not straightforward.
Score Interpretation
- ≥4 points: Wilson's disease diagnosis established
- 3 points: Wilson's disease possible — additional testing required
- ≤2 points: Wilson's disease unlikely
A score of ≥4 can be achieved without liver biopsy when clinical, biochemical, and/or genetic data are sufficiently weighted.
| Parameter | Finding | Score |
|---|---|---|
| Kayser-Fleischer rings | Present on slit-lamp examination | +2 |
| Neuropsychiatric symptoms | Tremor, dysarthria, dystonia, behavioral or psychiatric disturbance | +2 |
| Coombs-negative hemolysis | DAT-negative hemolytic anemia present | +1 |
| Urinary copper (without chelation) | >2× upper limit of normal (>100 µg/day) | +2 |
| Urinary copper (without chelation) | 1–2× upper limit of normal (40–100 µg/day) | +1 |
| Urinary copper on D-penicillamine challenge (pediatric) | >5× upper limit of normal after challenge dose | +2 |
| Liver copper (biopsy) | >4× ULN — hepatic copper >250 µg/g dry weight | +2 |
| Liver copper (biopsy) | 0.8–4× ULN — hepatic copper 50–250 µg/g dry weight | +1 |
| Rhodanine-positive granules (biopsy) | Present when quantitative copper measurement is not available | +1 |
| Serum ceruloplasmin | <0.1 g/L (<10 mg/dL) | +2 |
| Serum ceruloplasmin | 0.1–0.2 g/L (10–20 mg/dL) | +1 |
| ATP7B mutation analysis | Both disease-causing mutations identified | +4 |
| ATP7B mutation analysis | One disease-causing mutation identified | +1 |
Interactive scoring: Check criteria present in your patient — a score ≥4 establishes the diagnosis. The six highest-weight criteria (≥1 point each, including the +4 genetic criterion) are shown below.
Kayser-Fleischer rings (slit-lamp)
Present on slit-lamp examination
+2 points
Neuropsychiatric symptoms
Tremor, dysarthria, dystonia, behavioral or psychiatric disturbance
+2 points
Coombs-negative hemolysis
DAT-negative hemolytic anemia present
+1 point
24h urine copper >2× ULN (>100 µg/day)
Without chelation therapy
+2 points
Ceruloplasmin <0.1 g/L (<10 mg/dL)
Markedly low ceruloplasmin
+2 points
Both ATP7B mutations identified
Genetic testing confirms biallelic disease-causing mutations
+4 points
0 of 6 complete
Hepatic copper quantification
Hepatic copper >250 µg/g dry weight (normal <50 µg/g dry weight) is highly suggestive of Wilson's disease. Liver biopsy is useful when noninvasive testing is inconclusive, when fibrosis staging is needed, or when the Leipzig score falls in the indeterminate range (score of 3).Biopsy provides both histologic characterization and quantitative hepatic copper measurement, which contributes to the Leipzig score.
| Finding | Detail |
|---|---|
| Histology — early WD | Steatosis, glycogenated nuclei in hepatocytes (characteristic but nonspecific), mild hepatocyte ballooning |
| Histology — advanced WD | Hepatocyte necrosis, Mallory-Denk bodies, cirrhosis with bridging fibrosis; inflammatory infiltrate may resemble autoimmune hepatitis |
| Copper staining (Rhodanine / rubeanic acid) | Demonstrates copper granules histologically; insensitive for diffuse cytoplasmic copper (which predominates in early WD) — staining is most useful when copper is sequestered in lysosomes |
| Quantitative hepatic copper (atomic absorption spectroscopy) | >250 µg/g dry weight = highly suggestive of WD; >4× ULN scores +2 on Leipzig. More reliable than staining alone. |
| Pitfall: cholestatic liver disease | Hepatic copper can also be elevated in other chronic cholestatic liver diseases (PBC, PSC, biliary atresia) — histologic context and clinical correlation are essential |
Staining limitation
Rhodanine staining is negative in up to 30–40% of confirmed WD cases — particularly early disease where copper is diffusely distributed in the cytoplasm rather than concentrated in lysosomes. Do not rely on staining alone; request quantitative copper concentration whenever WD is suspected.The goal of treatment is to remove excess copper from tissues (chelation) and/or block intestinal copper absorption (zinc). Treatment is lifelong — discontinuation is associated with fulminant hepatic failure and death, even in patients who have been stable for years.
Historical First-Line
D-Penicillamine
- Mechanism: copper chelation → urinary excretion
- Dose: 750–1500 mg/day divided
- Now less preferred due to toxicity profile
- Major risk: paradoxical neurological worsening in 10–50% neurologic WD patients
- Side effects: hypersensitivity, drug-induced lupus, myasthenia gravis, nephropathy, pemphigus
Preferred First-Line
Trientine (TETA)
- Mechanism: copper chelation → urinary excretion
- Dose: 750–1500 mg/day on empty stomach
- Preferred over D-penicillamine — better tolerated
- Lower rate of neurological worsening
- Side effects: iron deficiency anemia; less immunologic toxicity
First-Line — Pre-symptomatic & Maintenance
Zinc Acetate / Gluconate
- Mechanism: induces intestinal metallothionein → blocks intestinal copper absorption → fecal copper excretion
- Dose: elemental zinc 50 mg TID (150 mg/day) on empty stomach
- Preferred in: pre-symptomatic patients, maintenance after chelation stabilization, pregnancy (lowest teratogenic risk)
- Side effects: GI upset (common, often transient)
- Less effective than chelators in acute symptomatic disease
Investigational
Tetrathiomolybdate
- Mechanism: chelation + copper absorption blockade
- May cause less neurological worsening than D-penicillamine during initial mobilization
- Not FDA-approved; not routinely available outside clinical trials
- Potential bone marrow toxicity
Monitoring targets during treatment
- 24-hour urine copper: Goal 200–500 µg/day during chelation (reflects copper mobilization); <75 µg/day on zinc maintenance (reflects adequate absorption blockade)
- Free (non-ceruloplasmin-bound) copper: Target 5–15 µg/dL; over-chelation leads to copper deficiency if free copper falls below 5 µg/dL
- CBC and urinalysis: Required at every visit for patients on D-penicillamine (monitoring for nephrotoxicity, cytopenias, proteinuria)
- Neurological examination: Assess at each visit; document trajectory of motor and psychiatric symptoms
Pregnancy guidance
WD treatment must continue throughout pregnancy — discontinuation risks fulminant ALF and is potentially fatal to both mother and fetus. Zinc is the preferred agent in pregnancy (lowest teratogenic risk and no fetal connective tissue effects). D-penicillamine is associated with connective tissue abnormalities in neonates; if a patient is stable on D-penicillamine, consider switching to trientine prior to or early in pregnancy. Trientine is preferred over D-penicillamine when chelation is required during pregnancy.Indications for liver transplantation in Wilson's disease
- WD-ALF — highest-priority indication; the only definitive life-saving intervention in acute fulminant disease; medical therapy alone is inadequate for WD-ALF
- Decompensated WD cirrhosis unresponsive to medical therapy — persistent ascites, hepatic encephalopathy, or variceal bleeding despite adequate chelation
- Recurrent hepatic decompensation despite adequate chelation and documented compliance
| Principle | Detail |
|---|---|
| ATP7B correction after transplant | The transplanted liver has normal ATP7B function — copper metabolism is corrected at its source. Following transplantation, copper accumulation ceases and serum ceruloplasmin normalizes. |
| Post-transplant chelation | Copper chelation therapy is NOT required after successful liver transplantation. The donor liver provides full ATP7B enzymatic activity. |
| Neurological outcomes after LT | Neurological and psychiatric manifestations may improve after successful liver transplantation, but outcomes for purely neuropsychiatric WD in the absence of significant hepatic disease are less predictable. |
| Transplant for neuropsychiatric WD (no liver disease) | Liver transplantation is not routinely performed for neuropsychiatric WD without liver disease — neurological benefit is uncertain and the risk-benefit analysis does not consistently support this indication. |
Listing urgency for WD-ALF
WD-ALF should be listed at highest urgency (Status 1A in the UNOS system). Unlike most metabolic diseases, transplantation in WD provides a true cure of the underlying metabolic defect — not merely supportive management of end-stage liver disease.Who to screen
Siblings and children of every confirmed WD patient should be evaluated, regardless of symptoms. Pre-symptomatic diagnosis allows treatment before organ damage occurs.| Evaluation component | Detail |
|---|---|
| Laboratory workup | Serum ceruloplasmin, total serum copper, calculated free copper, 24-hour urine copper, liver function tests (ALT, AST, bilirubin, albumin, INR) |
| Ophthalmologic evaluation | Slit-lamp examination for Kayser-Fleischer rings and sunflower cataracts — required in all at-risk individuals regardless of visual symptoms |
| Genetic testing | ATP7B mutation analysis if the proband's specific mutations are known — allows targeted genotyping in family members. Compound heterozygotes (two different ATP7B mutations) are common. |
| Sibling risk | Each sibling of a confirmed WD patient has a 25% probability of being affected (autosomal recessive inheritance; parents are obligate carriers) |
| Treatment — pre-symptomatic | Zinc is preferred for pre-symptomatic patients — well tolerated, effective at preventing copper accumulation when disease has not yet caused organ injury. Chelation reserved for those with evidence of organ involvement. |
Pearl: Pre-symptomatic treatment prevents organ damage
Siblings identified before symptom onset can be treated with zinc to prevent copper accumulation from ever reaching toxic tissue levels. This is one of the clearest examples in hepatology where family screening directly prevents morbidity — not just enables early detection.Clinical Case Vignette
A 22-year-old man presents with three days of progressive jaundice, confusion, and abdominal distension. He has no prior medical history and takes no medications. On exam he is encephalopathic (grade II) with scleral icterus and mild asterixis.
AST 340 IU/L | ALT 280 IU/L | ALP 45 IU/L (paradoxically low) | Total bilirubin 18 mg/dL | INR 2.8 | Albumin 2.6 g/dL | Creatinine 2.1 mg/dL
Hgb 8.2 g/dL | Reticulocytes elevated | Peripheral smear: schistocytes | Coombs (DAT): NEGATIVE
Serum ceruloplasmin: 11 mg/dL | Slit-lamp: Kayser-Fleischer rings present bilaterally
Work through the management step by step before the answers are revealed.